ALLR Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

Allarity Therapeutics Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerALLR

Market Cap26.7M

Cash RunwayRunway > 12 months

Next Catalystn/a

Public Research Snapshot

Allarity Therapeutics Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for LiPlaCis ® (Phase 2) using Small Molecule.

Pipeline

Asset	Indication	Modality	Stage	Public Note
Personalized Cancer Care. Realized.	n/a	Small Molecule	n/a	Public pipeline row
LiPlaCis ®	n/a	n/a	Phase 2	Public pipeline row
Irofulven	Metastatic Castration-Resistant Prostate Cancer Patients	n/a	Phase 2	Public pipeline row

Catalyst Preview

No public catalyst rows matched this view yet.

Cash Runway Preview

Estimated cash runway: Runway > 12 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT03643107	Phase 2	COMPLETED	15	2021-10-01

Scientific Context

literature_publication | Endometrial cancer: A Society of Gynecologic Oncology evidence-based review and recommendations, part II.
literature_publication | Endometrial cancer: A Society of Gynecologic Oncology evidence-based review and recommendations: Part I.
literature_publication | Botensilimab (Fc-enhanced anti-CTLA-4 antibody) plus balstilimab (anti-PD-1 antibody) in patients with treatment-refractory ovarian cancer.
literature_publication | Randomized study evaluating optimal dose, efficacy, and safety of E7386 plus lenvatinib versus treatment of physician's choice in advanced/recurrent endometrial carcinoma previously treated with platinum-based chemotherapy and immune checkpoint inhibitors.
literature_publication | Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial.

Want the full ALLR research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.